secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2024-06-25T23:59:59+00:00
Accession:  0001847903-24-000095
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Centessa shareholders approve all proposals at 2024 AGM
-------------------------------------------------------

- Directors Francesco De Rubertis, Saurabh Saha, and Mary Lynne Hedley re-elected with 67.8M, 76.4M, and 76.6M votes For respectively.
- KPMG LLP (UK) re-appointed as statutory auditor, and KPMG LLP (US) ratified as independent auditor, each with 88.9M For votes.
- Advisory resolution to approve directors' remuneration report passed with 76.7M For votes.
- Authority to allot shares up to £100,740 nominal and disapply pre-emption rights approved with 68.0M and 64.6M For votes respectively.
- All resolutions passed; no dividend recommended for FY2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790324000095/0001847903-24-000095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790324000095/cnta-20240625.htm
  HTML page:      https://secwatch.observer/filing/0001847903-24-000095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer